| Code | CSB-RA009438MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar referenced to the antibody described in patent US20170275370A1, targeting GIPR (glucose-dependent insulinotropic polypeptide receptor), also known as gastric inhibitory polypeptide receptor. GIPR is a class B G-protein-coupled receptor predominantly expressed on pancreatic beta cells, adipocytes, brain neurons, and bone cells. Upon binding its ligand GIP, GIPR activates adenylyl cyclase and cAMP signaling to stimulate glucose-dependent insulin secretion, promote fat deposition in adipose tissue, and regulate bone remodeling. While GIPR agonism enhances insulin secretion, paradoxically both GIPR agonism and antagonism have demonstrated efficacy in obesity treatment, with antagonism preventing weight gain by blocking GIP-mediated lipid accumulation in adipose tissue. The reference antibody is designed as a GIPR antagonist for metabolic disease research, particularly in combination with GLP-1 receptor agonists. This biosimilar provides researchers with a valuable tool for investigating GIPR biology, studying incretin hormone signaling, and exploring dual-pathway therapeutic strategies targeting both GIPR and GLP-1R in preclinical models of type 2 diabetes, obesity, and metabolic syndrome.
There are currently no reviews for this product.